Streetbeat News

Analyst Ratings

GHLD

BTIG analyst Eric Hagen has initiated coverage on Guild Holdings (NYSE:GHLD) with a Buy rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:35 pm

SABR

Cantor Fitzgerald analyst Brett Knoblauch initiates coverage on Sabre (NASDAQ:SABR) with an Overweight rating and a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:33 pm

RAPT

Leerink Partners analyst Thomas Smith downgraded RAPT Therapeutics from Outperform to Market Perform and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:21 pm

PANW

Rosenblatt analyst Catharine Trebnick downgraded Palo Alto Networks (PANW) from Buy to Neutral and reduced the price target from $290 to $265.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:19 pm

COMP

Gordon Haskett analyst Robert Mollins downgrades Compass (NYSE:COMP) from Hold to Underperform with a new price target of $2.25.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:15 pm

AMPL

Scotiabank analyst Nick Altmann downgraded Amplitude (NASDAQ:AMPL) from Sector Outperform to Sector Perform, indicating a neutral outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:12 pm

PANW

Loop Capital analyst Yun Kim downgrades Palo Alto Networks (NASDAQ:PANW) from Buy to Hold and sets a $300 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:09 pm

CDP

Jefferies analyst Peter Abramowitz upgrades COPT Defense (NYSE:CDP) from Hold to Buy and raises the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:06 pm

BCYC

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Bicycle Therapeutics (NASDAQ:BCYC) but lowers the price target from $57 to $55.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:04 pm

PATH

Analyst ratings for UiPath (NYSE:PATH) show a mix of bullish and bearish perspectives with 9 analysts offering evaluations over the past three months. The average 12-month price target for UiPath has increased to $22.33, up 17.53% from the previous target of $19.00. Several analysts from firms like Barclays, Canaccord Genuity, and JP Morgan have raised their price targets, reflecting a positive shift in expectations. UiPath's financial performance shows a solid revenue growth rate of 24.05% as of October 31, 2023, but struggles with below-industry averages in net margin, ROE, and ROA, indicating challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 12:01 pm